Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Haanen J, et al. Among authors: larkin j. Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18. Ann Oncol. 2022. PMID: 36270461 Free article. No abstract available.
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. McArthur GA, et al. Among authors: larkin j. Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7. Lancet Oncol. 2014. PMID: 24508103 Free PMC article. Clinical Trial.
Management of toxicities of immune checkpoint inhibitors.
Spain L, Diem S, Larkin J. Spain L, et al. Among authors: larkin j. Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6. Cancer Treat Rev. 2016. PMID: 26874776 Review.
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome".
Spain L, Larkin J, Martin-Liberal J. Spain L, et al. Among authors: larkin j. Cancer Immunol Immunother. 2016 Jun;65(6):769-70. doi: 10.1007/s00262-016-1845-2. Epub 2016 May 19. Cancer Immunol Immunother. 2016. PMID: 27194054 Free PMC article. No abstract available.
1,233 results